Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.

Xianwang WangYihua ShenXingxia WanXiaoqing HuWen-Qi CaiZijun WuQiang XinXiaoqing LiuJingang GuiHong-Yi XinHong-Wu Xin

Published in: Journal of translational medicine (2023)

OVs, which are advancing into clinical trials, are being envisioned as the frontier clinical anti-tumor agents coming soon.

Keyphrases